VSTM Verastem Inc
- Stocks
- Healthcare
- NASDAQ: VSTM
Price (delayed)
$7.92
Market cap
$487.44M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.5
Enterprise value
$407.83M
Relative Growth:
Rel. Growth:
17
Relative Strength:
Rel. Strength:
87
Relative Valuation:
Rel. Valuation:
1
Relative Profitability:
Rel. Profitability:
12
Verastem Oncology is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. The company's pipeline is focused on
Highlights
Verastem's equity has surged by 91% YoY
Verastem's quick ratio has increased by 6% YoY
Verastem's debt has soared by 102% YoY and by 10% from the previous quarter
VSTM's net income has dropped by 86% year-on-year and by 12% since the previous quarter
Key stats
What are the main financial stats of VSTM
Market
Valuations
Earnings
Shares outstanding
61.55M
Market cap
$487.44M
Enterprise value
$407.83M
Price to earnings (P/E)
N/A
Price to book (P/B)
12.07
Price to sales (P/S)
245.13
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
190.84
Revenue
$2.14M
Gross profit
$1.69M
Operating income
-$156.65M
Net income
-$166.56M
EBIT
-$163.67M
EBITDA
-$163.65M
Free cash flow
-$120.23M
Per share
Balance sheet
Liquidity
EPS
-$3.5
EPS diluted
-$3.73
Free cash flow per share
-$1.82
Book value per share
$0.66
Revenue per share
$0.03
TBVPS
$2.73
Total assets
$196.26M
Total liabilities
$160.21M
Debt
$84.72M
Equity
$36.06M
Working capital
$123.91M
Debt to equity
2.35
Current ratio
3.46
Quick ratio
3.31
Net debt/EBITDA
0.49
Margins
Efficiency
Dividend
EBITDA margin
-7,657.7%
Gross margin
79.1%
Net margin
-7,793.9%
Operating margin
-7,330.6%
Return on assets
-119.9%
Return on equity
N/A
Return on invested capital
-446.1%
Return on capital employed
-112.2%
Return on sales
-7,659%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VSTM stock price
How has the Verastem stock price performed over time
Intraday
-2.94%
1 week
-14.19%
1 month
-8.01%
1 year
104.65%
YTD
53.19%
QTD
-10.31%
Financial performance
How have Verastem's revenue and profit performed over time
Revenue
$2.14M
Gross profit
$1.69M
Operating income
-$156.65M
Net income
-$166.56M
Gross margin
79.1%
Net margin
-7,793.9%
VSTM's net income has dropped by 86% year-on-year and by 12% since the previous quarter
VSTM's gross profit has dropped by 83% since the previous quarter and by 83% year-on-year
VSTM's revenue has dropped by 79% since the previous quarter and by 79% year-on-year
The company's operating income has shrunk by 59% YoY and by 20% QoQ
Price vs fundamentals
How does VSTM's price correlate with its fundamentals
Growth
What is Verastem's growth rate over time
Valuation
What is Verastem stock price valuation
P/E
N/A
P/B
12.07
P/S
245.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
190.84
Verastem's EPS has decreased by 4.5% YoY and by 2.3% QoQ
The stock's P/B is 165% above its 5-year quarterly average of 4.7
Verastem's equity has surged by 91% YoY
VSTM's revenue has dropped by 79% since the previous quarter and by 79% year-on-year
Efficiency
How efficient is Verastem business performance
The ROA has plunged by 86% YoY but it has grown by 6% from the previous quarter
Dividends
What is VSTM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VSTM.
Financial health
How did Verastem financials performed over time
The total assets is 23% greater than the total liabilities
Verastem's total liabilities has soared by 144% YoY but it has decreased by 2.4% from the previous quarter
The total assets has surged by 86% year-on-year and by 49% since the previous quarter
Verastem's debt is 135% more than its equity
VSTM's debt to equity has surged by 199% since the previous quarter and by 6% year-on-year
Verastem's debt has soared by 102% YoY and by 10% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.